High BMI Linked to Better Immunotherapy Outcomes in NSCLC

Dylann Cohn-Emery
Published: Friday, Feb 14, 2020
Ganessan Kichenadasse, MBBS, FRACP, a medical oncology researcher at the Flinders Centre for Innovation in Cancer

Ganessan Kichenadasse, MBBS, FRACP

A high body mass index (BMI) at baseline may be independently associated with improved survival outcomes in patients with non–small cell lung cancer (NSCLC) who receive immune checkpoint inhibitor therapy, according to study results published recently in JAMA Oncology.1
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication